Literature DB >> 15525828

Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.

Ruka Włodzimierz1, Piotr Rutkowski, Zbigniew I Nowecki, Jadwiga Kulik, Anna Nasierowska-Guttmejer, Janusz A Siedlecki.   

Abstract

BACKGROUND: The aim of this study was to evaluate the role of melanoma gene expression as a marker of the presence of melanoma cells in lymphatic drainage routinely collected after lymphadenectomy and to correlate reverse transcriptase-polymerase chain reaction (RT-PCR) assay results with recurrence, survival, and prognostic factors.
METHODS: We collected 24-hour postoperative lymphatic drainage samples (between days 2 and 4) from 93 patients with stage III melanoma who underwent radical lymphadenectomy between May 2002 and November 2003. We used RT-PCR assays with primers specific for the tyrosinase and MART-1 (Melan-A) genes. The samples were considered positive if at least one marker was expressed. Median follow-up time was 12.8 months.
RESULTS: In 18 (19.4%) of 93 patients, the RT-PCR assay results were positive: in 8 of 18 for tyrosinase only, in 7 of 18 for MART-1 only, and in 3 of 18 for both markers. We observed a significantly higher recurrence rate in patients with positive RT-PCR results (15 of 18; 83%) than negative results (26 of 75; 35%; P = .0001). Positive results of RT-PCR correlated with the number of involved lymph nodes (P = .0001) and extracapsular extension of nodal metastases (P = .03). We observed significant differences in overall and disease-free survival for RT-PCR-positive and -negative patients in univariate and multivariate analyses.
CONCLUSIONS: We observed positive RT-PCR assay results for melanoma cells in the lymphatic drainages of approximately 20% of patients after lymphadenectomy. This correlated significantly with early recurrence and shorter survival. These results may suggest that the RT-PCR assay could be useful for routinely analyzing postoperatively collected lymphatic drainage in stage III melanoma patients and for predicting disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525828     DOI: 10.1245/ASO.2004.03.023

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Postlymphadenectomy Analysis of Exosomes from Lymphatic Exudate/Exudative Seroma of Melanoma Patients.

Authors:  Susana García-Silva; Pilar Ximénez-Embún; Javier Muñoz; Héctor Peinado
Journal:  Methods Mol Biol       Date:  2021

2.  A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Authors:  Ahmad A Tarhini; Theofanis Floros; Hui-Min Lin; Yan Lin; Zahra Rahman; Madeeha Ashraf; Priyanka Vallabhaneni; Cindy Sander; Uma N M Rao; Monica Panelli; William A LaFramboise; John M Kirkwood
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

3.  Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.

Authors:  Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka
Journal:  Ann Surg Oncol       Date:  2010-07-07       Impact factor: 5.344

4.  Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation.

Authors:  Susana García-Silva; Alberto Benito-Martín; Sara Sánchez-Redondo; Alberto Hernández-Barranco; Pilar Ximénez-Embún; Laura Nogués; Marina S Mazariegos; Kay Brinkmann; Ana Amor López; Lisa Meyer; Carlos Rodríguez; Carmen García-Martín; Jasminka Boskovic; Rocío Letón; Cristina Montero; Mercedes Robledo; Laura Santambrogio; Mary Sue Brady; Anna Szumera-Ciećkiewicz; Iwona Kalinowska; Johan Skog; Mikkel Noerholm; Javier Muñoz; Pablo L Ortiz-Romero; Yolanda Ruano; José L Rodríguez-Peralto; Piotr Rutkowski; Héctor Peinado
Journal:  J Exp Med       Date:  2019-04-11       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.